Haemonetics Co. (NYSE:HAE) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC lessened its position in Haemonetics Co. (NYSE:HAE) by 0.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 54,525 shares of the medical instruments supplier’s stock after selling 279 shares during the period. MetLife Investment Management LLC’s holdings in Haemonetics were worth $4,383,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Janus Henderson Group PLC grew its position in Haemonetics by 26.8% in the 1st quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier’s stock worth $2,536,000 after purchasing an additional 6,287 shares during the last quarter. First Hawaiian Bank grew its holdings in Haemonetics by 55.2% in the 2nd quarter. First Hawaiian Bank now owns 6,165 shares of the medical instruments supplier’s stock worth $510,000 after buying an additional 2,192 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in Haemonetics by 311.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 25,775 shares of the medical instruments supplier’s stock worth $2,132,000 after buying an additional 19,510 shares in the last quarter. CWM LLC increased its position in Haemonetics by 40.5% in the 2nd quarter. CWM LLC now owns 36,526 shares of the medical instruments supplier’s stock valued at $3,022,000 after acquiring an additional 10,537 shares during the period. Finally, Cardinal Capital Management raised its stake in Haemonetics by 3.8% during the 2nd quarter. Cardinal Capital Management now owns 14,832 shares of the medical instruments supplier’s stock valued at $1,227,000 after acquiring an additional 549 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on HAE shares. Bank of America began coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price target on the stock. Citigroup lowered their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a research note on Friday, November 15th. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a research note on Friday, November 8th. Finally, JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Trading Down 0.5 %

Haemonetics stock opened at $87.47 on Monday. Haemonetics Co. has a 1 year low of $70.25 and a 1 year high of $97.97. The firm’s 50 day moving average price is $79.99 and its two-hundred day moving average price is $82.05. The firm has a market cap of $4.39 billion, a price-to-earnings ratio of 36.29, a price-to-earnings-growth ratio of 1.36 and a beta of 0.32. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. During the same period in the previous year, the firm earned $0.99 earnings per share. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, research analysts predict that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.